Association Between C-Peptide Level and Subclinical Myocardial Injury

Abstract

BackgroundPrevious studies have confirmed an association between C-peptide levels with the risk of cardiometabolic diseases. However, whether circulating C-peptide was related to subclinical myocardial injury (SC-MI) remains unknown.MethodsA total of 3,752 participants without a history of cardiovascular diseases were included in our study from National Health and Nutrition Examination Survey III (NHANES III). Multivariable linear regression was performed to explore the correlation between C-peptide and cardiac injury score (CIIS). Multivariate logistic regression was used to examine the association between C-peptide quartile and SC-MI.ResultsCirculating C-peptide was significantly associated with CIIS (β:0.09, 95% confidence interval [CI]: 0.00–0.17; p = 0.041). Compared with the lowest quartile, the highest quartile of circulating C-peptide increased a 1.48-fold risk of SC-MI (Odds ratio = 1.66, 95% CI: 1.18–1.87; p = 0.001).ConclusionsThe level of C-peptide was independently associated with CIIS and SC-MI, which could serve as a new risk factor of SC-MI.

Blood C‐peptide concentration as a proxy marker of cardiovascular disease: An observational cross‐sectional study

“…25,26 Basal C-peptide levels have also been linked with carotid artery intima-media thickness in T2DM patients 27,28 and myocardial infarction (MI) in the general population. 29 As such, the current study contributes to the expanding body of knowledge supporting the use of C-peptide as a stand-in biomarker for CVD. In this study, C-peptide had high specificity (96.1%) and sensitivity (91.3%),…”

The bidirectional association of C-peptide with cardiovascular risk in nondiabetic adults and patients with newly diagnosed type 2 diabetes mellitus: a retrospective cohort study

“…However, in nondiabetic individuals, several studies reported a positive linear association between C-peptide and arterial stiffness markers [ 7 , 22 ]. A higher level of C-peptide had been reported to be correlated with higher risks of subclinical myocardial injury and all-cause and cardiovascular-related mortality [ 8 – 10 , 23 ]. Recently, several adverse effects of C-peptide at a low level had been reported [ 24 , 25 ].…”

“…BMI body mass index, CI confidence interval, FPG fasting plasma glucose, HbA1c hemoglobin A1c, HOMA-IR homeostasis model assessment of insulin resistance, HR hazard ratio, LDL cholesterol low-density lipoprotein cholesterol, T2DM type 2 diabetes mellitus, 2hPG 2 h plasma glucose C-peptide and arterial stiffness markers [7,22]. A higher level of C-peptide had been reported to be correlated with higher risks of subclinical myocardial injury and allcause and cardiovascular-related mortality [8][9][10]23]. Recently, several adverse effects of C-peptide at a low level had been reported [24,25].…”

Insulin administered intranasally, but not proinsulin C-peptide, normalises hormonal parameters and hypothalamic gene expression in male rats with type 2 diabetes and obesity

“…Имеются все основания полагать, что повышение уровня С-пептида в крови ассоциировано с повышением содержания С-пептида в мозге, тем более что рецепторный механизм в транспорте С-пептида через ГЭБ, который мог бы меняться в условиях гипер-С-пептидемии, не показан. Имеются данные о том, что повышенные уровни С-пептида при СД2 и ожирении могут негативно влиять на функционирование микрососудов головного мозга и быть причиной ряда функциональных расстройств нервной и сердечно-сосудистой систем (Alves et al 2019;Chen et al 2021;Wang et al 2021). В основе этого лежит доказанное тромболитическое действие С-пептида при его высоких концентрациях, а также стимулирующее влияние С-пептида на рост гладкомышечных клеток сосудов, приводящее к атеросклеротическим изменениям (Alves et al 2019).…”